5 Key Takeaways

• 1

  Pharmacogenetic testing is increasing in requests and importance, prompting a task force to address its integration into clinical practice.

• 2

  Barriers to pharmacogenetic testing include lack of access, missing clinical guidelines, and unclear reimbursement strategies.

• 3

  Evidence supports the association between genetic variants and drug sensitivity, with significant findings for at least 60 different drugs.

• 4

  Despite evidence, clinical community hesitates to adopt pharmacogenetic testing, as seen with CYP2D6 and CYP2C19 testing.

• 5

  The task force aims to implement pharmacogenetics into patient care globally within two years by creating guidelines and networks.